Robert Rosen - 22 Aug 2022 Form 4 Insider Report for LA JOLLA PHARMACEUTICAL CO

Role: Director
Signature: /s/ Michael Hearne, by power of attorney for Robert H. Rosen
Issuer symbol: N/A
Transactions as of: 22 Aug 2022
Net transactions value: $0
Form type: 4
Filing time: 24 Aug 2022, 20:27:43 UTC
Previous filing: 14 Jan 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Shares	Change %	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LJPC	Stock Option (Right to Buy)	Disposed to Issuer	-18,000	-100%	22 Aug 2022	Common Stock	18,000	$8.52	Direct	F1, F2
transaction	LJPC	Stock Option (Right to Buy)	Disposed to Issuer	-10,000	-100%	22 Aug 2022	Common Stock	10,000	$19.69	Direct	F1, F2
transaction	LJPC	Stock Option (Right to Buy)	Disposed to Issuer	-10,000	-100%	22 Aug 2022	Common Stock	10,000	$28.24	Direct	F1, F2
transaction	LJPC	Stock Option (Right to Buy)	Disposed to Issuer	-10,000	-100%	22 Aug 2022	Common Stock	10,000	$19.19	Direct	F1, F2
transaction	LJPC	Stock Option (Right to Buy)	Disposed to Issuer	-10,000	-100%	22 Aug 2022	Common Stock	10,000	$28.10	Direct	F1, F2
transaction	LJPC	Stock Option (Right to Buy)	Disposed to Issuer	-12,000	-100%	22 Aug 2022	Common Stock	12,000	$5.99	Direct	F1, F2
transaction	LJPC	Stock Option (Right to Buy)	Disposed to Issuer	-12,000	-100%	22 Aug 2022	Common Stock	12,000	$3.93	Direct	F1, F2
transaction	LJPC	Stock Option (Right to Buy)	Disposed to Issuer	-30,000	-100%	22 Aug 2022	Common Stock	30,000	$4.53	Direct	F1, F2
transaction	LJPC	Stock Option (Right to Buy)	Disposed to Issuer	-30,000	-100%	22 Aug 2022	Common Stock	30,000	$4.81	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Robert Rosen is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time").
F2	(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.

Content

This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time").

(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.